Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669 for 2.0 Contact Hours.
PER Pulse™ Recaps
for the Working Group to Personalize Multidisciplinary Care in Patients with Lung Cancer: Updates and Evolving Concepts for Nurses symposium focus on targeted agents, toxicity management, and liquid biopsies for patients with lung cancer that were discussed by the expert faculty at this program.
This activity is supported by an educational grant from AstraZeneca.
This educational activity is geared toward practical applications of treatment strategies in the clinic. Key data related to a live symposium held at a recent oncology nursing meeting, that focused on the treatment of lung cancer, are now available as downloadable slides. Participants can test their knowledge through interactive clinical vignettes and view short video clips from the faculty to gain an expert perspective on clinical scenarios they face in the care of their patients with lung cancer. Due to the overwhelming amount of new information concerning the treatment of lung cancer with targeted agents, combined with evolving methodologies in using molecular profiling tools and techniques to guide therapy, educational activities that showcase expert discussions—combined with sharing of best practices—are key for the practitioners tasked with managing these challenging scenarios.
Instructions For This Activity & Receiving Credit
This educational program is directed toward nurses and other health care professionals with an interest in the treatment of lung cancers.
Benjamin Levy, MD
Assistant Professor, Icahn School of Medicine
Medical Director, Thoracic Oncology Program, Mount Sinai Health Systems
Associate Director, Cancer Clinical Trials Office, Mount Sinai Hospital
Mount Sinai Hospital
New York, NY
Disclosure: Consultant: Celgene, AstraZeneca, Lilly, Genentech, Pfizer, Merck; Speaker’s Bureau: Lilly, Genentech.
Karen Lee, MSN, FNP-BC
Mount Sinai Hospital
New York, NY
Disclosure: Consultant: Pfizer; Speaker’s Bureau: Pfizer, Bristol-Meyers Squibb.
Laura Brennan FNP-C, AOCNP
Division of Hematology & Oncology
UC Davis Medical Center
Disclosure: No relevant financial relationships with commercial interests.
Jonathan Riess, MD, MS
Assistant Professor of Medicine
Division of Hematology Oncology
UC Davis Comprehensive Cancer Center
Disclosure: Grant/Research Support: Merck, Novartis, Millennium; Consultant: Celgene, Ariad, Clovis.
The staff of Physicians' Education Resource®, LLC, have no relevant financial relationships with commercial interests.
It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME/CE activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.
This CME/CE activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.
Oncology Briefings™: Updates in Therapeutic Options and Approaches for Tenosynovial Giant Cell Tumors
Apr 28, 2018
April 28, 2018
New York, NY